Registry of Subjects at Risk of Pancreatic Cancer

Status Recruiting

Clinical Trial Summary

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Clinical Trial Description

Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to improve survival might be early detection. Within years, many predisposing diseases or genetic conditions have been identified, thus screening/surveillance have been established worldwide. A registry of subjects at risk of pancreatic cancer will has been built up to investigate the possibility of diagnosis pancreatic cancer, or one if its predisposing lesions. Inclusion criteria will be adopted as "enrollment criteria". According to this, individuals > 18 years old will be enrolled; their familiar history and/or genetic predisposition will be collected, as well as current or previous medical records/medications data. Thereafter, according to specific age-based criteria, those individuals initially enrolled will be will be considered for a "surveillance protocol" ("interventional follow-up criteria") and they will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography according to the pancreatologist's prescription at each participating center. Individuals suffering from the following conditions will be enrolled: familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16 mutation with at least one first- or second-degree relative suffering from pancreatic cancer; hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or second-degree relative suffering from pancreatic cancer. ;

Study Design

Related Conditions & MeSH terms

BRCA1 Mutation
BRCA2 Mutation
Colorectal Neoplasms, Hereditary Nonpolyposis
Dysplastic Nevus Syndrome
Familial Pancreatic Cancer
FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
Hereditary Pancreatitis
Lynch Syndrome
Melanoma
Pancreatic Neoplasms
Pancreatitis
Pancreatitis, Chronic
Peutz-Jeghers Syndrome
Syndrome

Clinical Trial Details

NCT number	NCT04095195
Study type	Observational
Source	Associazione Italiana per lo Studio del Pancreas
Contact	Salvatore Paiella, MD, PhD
Phone	00390458126009
Email	salvatore.paiella@univr.it
Status	Recruiting
Phase
Start date	August 20, 2019
Completion date	September 20, 2045

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00217737` - Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Phase 3
Completed	`NCT00905710` - Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome	N/A
Active, not recruiting	`NCT02194387` - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	N/A
Recruiting	`NCT04909671` - Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.	N/A
Recruiting	`NCT04379999` - Atorvastatin ± Aspirin in Lynch Syndrome Syndrome	Early Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed	`NCT01845753` - Molecular Screening for Lynch Syndrome in Denmark
Completed	`NCT01216930` - Molecular Screening for Lynch Syndrome in Southern Denmark	N/A
Not yet recruiting	`NCT05963191` - CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome	N/A
Active, not recruiting	`NCT02912559` - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Phase 3
Recruiting	`NCT04978350` - Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study	N/A
Active, not recruiting	`NCT03832985` - Pediatric Reporting of Adult-Onset Genomic Results	Early Phase 1
Withdrawn	`NCT04778566` - Evaluating the Cologuard Test for Use in Lynch Syndrome
Completed	`NCT02570516` - NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome	N/A
Completed	`NCT01823471` - I-Scan For Colon Polyp Detection In HNPCC	N/A
Recruiting	`NCT02813824` - Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome	Phase 3
Recruiting	`NCT05078866` - Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients	Phase 1/Phase 2
Recruiting	`NCT03744962` - MSI in Circulatory DNA of Endometrial Cancer
Recruiting	`NCT04711434` - PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients	Phase 3
Completed	`NCT04131062` - Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Registry of Subjects at Risk of Pancreatic Cancer — IRFARPC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms